Skip to main content
. Author manuscript; available in PMC: 2019 Mar 6.
Published in final edited form as: Kidney Blood Press Res. 2018 Mar 6;43(2):329–349. doi: 10.1159/000487902

Fig. 5.

Fig. 5

Effects of two weeks treatment with renin-angiotensin (RAS) blockade (an angiotensin converting enzyme inhibitor and an angiotensin II receptor blocker) and the two-drug RAS blockade combined with the soluble epoxide hydrolase (sEH) inhibitor cis-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid on kidney CYP2C23 gene (A) and protein (B) and kidney sEH gene (C) and protein (D) expressions in sham-operated Hannover Sprague-Dawley (HanSD, transgene-negative), in heterozygous Ren-2 transgenic rats (TGR), and in 5/6 nephrectomized (5/6 NX) TGR, untreated (water). *P<0.05 compared with shamoperated HanSD rats. #P<0.05 compared with all the other groups.